US20070232808A1 - Process for preparing heterocyclic derivatives - Google Patents

Process for preparing heterocyclic derivatives Download PDF

Info

Publication number
US20070232808A1
US20070232808A1 US11/693,757 US69375707A US2007232808A1 US 20070232808 A1 US20070232808 A1 US 20070232808A1 US 69375707 A US69375707 A US 69375707A US 2007232808 A1 US2007232808 A1 US 2007232808A1
Authority
US
United States
Prior art keywords
alkyl
compounds
alkoxy
group
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/693,757
Inventor
Sergio Bacchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Assigned to GLAXO GROUP LIMITED reassignment GLAXO GROUP LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BACCHI, SERGIO
Publication of US20070232808A1 publication Critical patent/US20070232808A1/en
Priority to US12/608,184 priority Critical patent/US7838680B2/en
Assigned to GLAXO GROUP LIMITED reassignment GLAXO GROUP LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BACCHI, SERGIO
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention relates to a novel process, useful for preparing key intermediates in the synthesis of various compounds, among them compounds which are potent and specific antagonists of D3 receptors.
  • the present invention relates to a novel process for preparing thiazole or triazole derivatives of formula (I)
  • C1-C6 alkyl refers to a linear or branched alkyl group containing from 1 to 6 carbon atoms; examples of such groups include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert butyl, pentyl or hexyl.
  • halogen refers to a fluorine, chlorine, bromine or iodine atom.
  • halo C1-C6 alkyl means an alkyl group having one or more carbon atoms and wherein at least one hydrogen atom is replaced with halogen such as for example a trifluoromethyl group and the like.
  • C1-C6 thioalkyl may be a linear or a branched chain thioalkyl group, for example thiomethyl, thioethyl, thiopropyl, thioisopropyl, thiobutyl, thiosec-butyl, thiotert-butyl and the like.
  • C2-C6 alkenyl defines straight or branched chain hydrocarbon radicals containing one or more double bond and having from 2 to 6 carbon atoms such as, for example, ethenyl, 2-propenyl, 3-butenyl, 2-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2-butenyl or 3-hexenyl and the like.
  • C1-C6 alkoxy group may be a linear or a branched chain alkoxy group, for example methoxy, ethoxy, propoxy, prop-2-oxy, butoxy, but-2-oxy or methylprop-2-oxy and the like.
  • halo C1-C6 alkoxy group may be a C1-C6 alkoxy group as defined before substituted with at least one halogen, preferably fluorine, such as OCHF 2 , or OCF 3 .
  • C2-C6 alkynyl defines straight or branched chain hydrocarbon radicals containing one or more triple bond and having from 2 to 6 carbon atoms including acetylenyl, propynyl, 1-butynyl, 1-pentynyl, 3-methyl-1-butynyl and the like.
  • aryl means an aromatic carbocyclic moiety such as phenyl, biphenyl or naphthyl.
  • heteroaryl means an aromatic heterocycle ring of 5 to 10 members and having at least one heteroatom selected from nitrogen, oxygen and sulfur, and containing at least 1 carbon atom, including both mono-and bicyclic ring systems.
  • heteroaryls include (but are not limited to) furyl, benzofuranyl, thiophenyl, benzothiophenyl, pyrrolyl, indolyl, isoindolyl, azaindolyl, pyridyl, quinolinyl, isoquinolinyl, oxazolyl, isooxazolyl, benzoxazolyl, pyrazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, triazolyl, tetrazolyl, quinazolinyl, and benzodioxolyl.
  • 5-6 membered heterocycle means, according to the above definition, a 5-6 monocyclic heterocyclic ring which is either saturated, unsaturated or aromatic, and which contains from 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur, and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized.
  • Heterocycles include heteroaryls as defined above. The heterocycle may be attached via any heteroatom or carbon atom.
  • the term includes (but is not limited to) morpholinyl, pyridinyl, pyrazinyl, pyrazolyl, thiazolyl, triazolyl, imidazolyl, oxadiazolyl, oxazolyl, isoxazolyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like.
  • HOBt and its by-products have an explosive nature and DCC and its by-product are always difficult to fully remove.
  • the process solves the above problems by using n-propane phosphonic cyclic anhydride, T3P, as condensation agent.
  • T3P was first used in the peptide synthesis in 1980 by H. Wissmann (Angew. Chem., 1980, 92, 129) and is steadily gaining importance in organic synthesis because is less toxic and safer compared to other common condensation agents, such as DCC.
  • T3P is used as 50% solution in ethyl acetate in the process of the present invention and does not need the isolation of the intermediate hydrazine-carbothiamide.
  • T3P is available as 50% solution in DMF (dimethylformamide) and may be employed in the process of the present invention.
  • the starting material, the heterocyclic carboxylic acid, generally commercially available or which may be prepared according to known methods in the literature, in an amount of 1 equivalent may be conveniently dissolved in the appropriate solvent (for example dimethylformamdide; ethyl acetate; acetonitrile and tetrahydrofurane and other polar aprotic solvent) and treated with a slightly excess of derivatives of 3-thiosemicarbazide (1.10 eq), such as 4-methyl derivative. Then an organic base (e.g. triethylamine, diisopropylethylamine and possibly other aliphatic of aromatic amines) is added at RT.
  • the appropriate solvent for example dimethylformamdide; ethyl acetate; acetonitrile and tetrahydrofurane and other polar aprotic solvent
  • derivatives of 3-thiosemicarbazide (1.10 eq)
  • an organic base e.g. triethylamine
  • N-propane phosphonic cyclic anhydride (50% w/w in ethyl acetate) may be then added at a temperature ranging from 0 to 40 degrees dropwise. In case the addition is made at about 0° C., the temperature is then maintained below 15° C. over 20-60 minutes. The resulting mixture was then stirred at 20° C. for 2-16 hours.
  • the mixture is then diluted with an aqueous solution of an appropriate inorganic base until basic pH was reached.
  • the suitable base may be selected among: potassium carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide.
  • the resulting bi-phasic mixture (when observed) is then allowed separating and the upper organic layer discarded.
  • the aqueous layer is then heated to 50-90° C. (internal temperature) for half an hour to several hours until reaction completion.
  • an appropriate mineral acid e.g. HCl 37%) is then slowly added to adjust the pH as needed. (4 to 8).
  • the suspension is then generally stirred for 2-16 hours, then the solid was filtered, washed with pure water and dried in a vacuum oven at 40-60° C. until dryness.
  • the final product is isolated from the aqueous mixture uncontaminated by phosphorous derivatives.
  • Step 1 Time-Reserv.A-Reserv.B Time 0 min 100%
  • Step 2 Time-Reserv.A-Reserv.B Time 8 min 5%
  • Step 3 Time-Reserv.A-Reserv.B Time 8.01 min 100%
  • the mixture was diluted with NaOH 4 M (120.0 mL). The resulting bi-phasic mixture was allowed separating and the upper organic layer discarded.
  • the suspension was stirred for 8 hours, then the solid was filtered and washed with water (60 mL), and it was dried in a vacuum oven at 40° C. overnight.
  • the suspension was cooled to 5° C. and the solid was filtered and washed with water, and it was then dried in a vacuum oven at 40° C. overnight.
  • the solid was filtered and it was then dried in a vacuum oven at 40° C. overnight.
  • the solid was filtered and washed with water (3 times with 20 mL), and it was then dried in a vacuum oven at 40° C. overnight.
  • mixture was allowed to reach ambient temperature and stirred for 2 hours under nitrogen.
  • the pH of the mixture was checked over time and pH adjusted to 12 if necessary. The heating was kept for a total amount of 3 hours.
  • the mixture was filtered, the cake washed with 22.5 mL of water and the collected solid dried under vacuum oven at 40° C. for 5 hours.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

The present invention relates to a novel process, useful for preparing key intermediates of formula (I) in the synthesis of various compounds, among them compounds which are potent and specific antagonists of D3 receptors,
Figure US20070232808A1-20071004-C00001
in which
    • X may be Nitrogen or Sulfur;
    • Het means aryl or heteroaryl; each of which may be substituted by 1 to 4 groups J selected from:
      • halogen, C1-C6 alkyl C1-C6 alkoxy, halo C1-C6 alkyl C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, —C(O)R1, nitro, hydroxy, —NR2R3, cyano or a group Z;
    • R1 is a C1-C4 alkyl —OR3 or —NR3R4;
    • R2 is hydrogen or C1-C6 alkyl;
    • R3 is hydrogen or C1-C6 alkyl;
    • R is H, C1-C6 alkyl aryl, benzyl; each of which may be substituted by 1 to 4 groups J;
    • according to the following Scheme 1:
Figure US20070232808A1-20071004-C00002
in which
    • step a means a reaction in basic conditions of compounds (IIA) with 3-thiosemicarbazide derivatives, followed by a treatment with an inorganic base and n-propane phosphonic cyclic anhydride and final pH adjustment with inorganic acids to give compounds of formula (II).

Description

  • The present invention relates to a novel process, useful for preparing key intermediates in the synthesis of various compounds, among them compounds which are potent and specific antagonists of D3 receptors.
  • The present invention relates to a novel process for preparing thiazole or triazole derivatives of formula (I)
  • Figure US20070232808A1-20071004-C00003
  • in which
      • X may be Nitrogen or Sulfur;
      • Het means aryl or heteroaryl; each of which may be substituted by 1 to 4 groups J selected from:
        • halogen, C1-C6 alkyl C1-C6 alkoxy, halo C1-C6 alkyl C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, —C(O)R1, nitro, hydroxy, —NR2R3, cyano or a group Z;
      • R1 is a C1-C4 alkyl —OR3 or —NR3R4;
      • R2 is hydrogen or C1-C6 alkyl;
      • R3 is hydrogen or C1-C6 alkyl;
      • R is H, C1-C6 alkyl aryl, benzyl; each of which may be substituted by 1 to 4 groups J;
      • according to the following Scheme 1:
  • Figure US20070232808A1-20071004-C00004
  • in which
      • step a means a reaction in basic conditions of compounds (IIA) with 3-thiosemicarbazide derivatives, followed by a treatment with an inorganic base and n-propane phosphonic cyclic anhydride and final pH adjustment with inorganic acids to give compounds of formula (II).
  • The term C1-C6 alkyl as used herein as a group or a part of the group refers to a linear or branched alkyl group containing from 1 to 6 carbon atoms; examples of such groups include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert butyl, pentyl or hexyl.
  • The term halogen refers to a fluorine, chlorine, bromine or iodine atom.
  • The term halo C1-C6 alkyl, means an alkyl group having one or more carbon atoms and wherein at least one hydrogen atom is replaced with halogen such as for example a trifluoromethyl group and the like.
  • The term C1-C6 thioalkyl may be a linear or a branched chain thioalkyl group, for example thiomethyl, thioethyl, thiopropyl, thioisopropyl, thiobutyl, thiosec-butyl, thiotert-butyl and the like.
  • The term C2-C6 alkenyl defines straight or branched chain hydrocarbon radicals containing one or more double bond and having from 2 to 6 carbon atoms such as, for example, ethenyl, 2-propenyl, 3-butenyl, 2-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2-butenyl or 3-hexenyl and the like.
  • The term C1-C6 alkoxy group may be a linear or a branched chain alkoxy group, for example methoxy, ethoxy, propoxy, prop-2-oxy, butoxy, but-2-oxy or methylprop-2-oxy and the like.
  • The term halo C1-C6 alkoxy group may be a C1-C6 alkoxy group as defined before substituted with at least one halogen, preferably fluorine, such as OCHF2, or OCF3.
  • The term C2-C6 alkynyl defines straight or branched chain hydrocarbon radicals containing one or more triple bond and having from 2 to 6 carbon atoms including acetylenyl, propynyl, 1-butynyl, 1-pentynyl, 3-methyl-1-butynyl and the like.
  • The term aryl means an aromatic carbocyclic moiety such as phenyl, biphenyl or naphthyl.
  • The term heteroaryl means an aromatic heterocycle ring of 5 to 10 members and having at least one heteroatom selected from nitrogen, oxygen and sulfur, and containing at least 1 carbon atom, including both mono-and bicyclic ring systems.
  • Representative heteroaryls include (but are not limited to) furyl, benzofuranyl, thiophenyl, benzothiophenyl, pyrrolyl, indolyl, isoindolyl, azaindolyl, pyridyl, quinolinyl, isoquinolinyl, oxazolyl, isooxazolyl, benzoxazolyl, pyrazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, triazolyl, tetrazolyl, quinazolinyl, and benzodioxolyl.
  • The term 5-6 membered heterocycle means, according to the above definition, a 5-6 monocyclic heterocyclic ring which is either saturated, unsaturated or aromatic, and which contains from 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur, and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized. Heterocycles include heteroaryls as defined above. The heterocycle may be attached via any heteroatom or carbon atom. Thus, the term includes (but is not limited to) morpholinyl, pyridinyl, pyrazinyl, pyrazolyl, thiazolyl, triazolyl, imidazolyl, oxadiazolyl, oxazolyl, isoxazolyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like.
  • Compounds of formula (II) can be useful, but are not limited to, for the preparation of D3 antagonists of formula (IA), as disclosed in WO2005/080382:
  • Figure US20070232808A1-20071004-C00005
  • wherein
      • G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl, indazolyl;
      • p is an integer ranging from 0 to 5;
      • R1 is independently selected from a group consisting of: halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl; or corresponds to a group R5;
      • R2 is hydrogen or C1-4alkyl;
      • R3 is C1-4alkyl;
      • R4 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl;
      • R5 is a moiety selected from the group consisting of: isoxazolyl, —CH2—N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl, 2-pyrrolidinonyl, and such a group is optionally substituted by one or two substituents selected from: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl;
        and when R1 is chlorine and p is 1, such R1 is not present in the ortho position with respect to the linking bond to the rest of the molecule; and when R1 corresponds to R5, p is 1.
  • The preparation of compounds of formula (II) described in WO2005/080382 employed 1-hydroxybenzotriazole (HOBt) together with 1,3-dicyclohexylcarbodiimide (DCC).
  • The disadvantages of this reagents at an industrial level may be summarized as follows: HOBt and its by-products have an explosive nature and DCC and its by-product are always difficult to fully remove.
  • The process solves the above problems by using n-propane phosphonic cyclic anhydride, T3P, as condensation agent.
  • Figure US20070232808A1-20071004-C00006
  • The T3P was first used in the peptide synthesis in 1980 by H. Wissmann (Angew. Chem., 1980, 92, 129) and is steadily gaining importance in organic synthesis because is less toxic and safer compared to other common condensation agents, such as DCC.
  • The reagent does not afford any water insoluble by-product. T3P is used as 50% solution in ethyl acetate in the process of the present invention and does not need the isolation of the intermediate hydrazine-carbothiamide. Similarly, T3P is available as 50% solution in DMF (dimethylformamide) and may be employed in the process of the present invention.
  • The process of the present invention can be depicted in more details as follows:
  • Figure US20070232808A1-20071004-C00007
  • The starting material, the heterocyclic carboxylic acid, generally commercially available or which may be prepared according to known methods in the literature, in an amount of 1 equivalent may be conveniently dissolved in the appropriate solvent (for example dimethylformamdide; ethyl acetate; acetonitrile and tetrahydrofurane and other polar aprotic solvent) and treated with a slightly excess of derivatives of 3-thiosemicarbazide (1.10 eq), such as 4-methyl derivative. Then an organic base (e.g. triethylamine, diisopropylethylamine and possibly other aliphatic of aromatic amines) is added at RT.
  • N-propane phosphonic cyclic anhydride (50% w/w in ethyl acetate) may be then added at a temperature ranging from 0 to 40 degrees dropwise. In case the addition is made at about 0° C., the temperature is then maintained below 15° C. over 20-60 minutes. The resulting mixture was then stirred at 20° C. for 2-16 hours.
  • The mixture is then diluted with an aqueous solution of an appropriate inorganic base until basic pH was reached. The suitable base may be selected among: potassium carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide.
  • The resulting bi-phasic mixture (when observed) is then allowed separating and the upper organic layer discarded. The aqueous layer is then heated to 50-90° C. (internal temperature) for half an hour to several hours until reaction completion.
  • After cooling down to 20° C., an appropriate mineral acid, (e.g. HCl 37%) is then slowly added to adjust the pH as needed. (4 to 8).
  • The suspension is then generally stirred for 2-16 hours, then the solid was filtered, washed with pure water and dried in a vacuum oven at 40-60° C. until dryness. The final product is isolated from the aqueous mixture uncontaminated by phosphorous derivatives.
  • EXAMPLES
  • In the Examples unless otherwise stated:
  • All temperatures refers to ° C. Infrared spectra were measured on a FT-IR instrument. Compounds were analysed by direct infusion of the sample dissolved in acetonitrile into a mass spectra operated in positive electro spray (ES+) ionisation mode. Proton Magnetic Resonance (1H-NMR) spectra were recorded at 400 MHz, chemical shifts are reported in ppm downfield (d) from Me4Si, used as internal standard, and are assigned as singlets (s), broad singlets (bs), doublets (d), doublets of doublets (dd), triplets (t), quartets (q) or multiplets (m). Column chromathography was carried out over silica gel (Merck AG Darmstaadt, Germany). The following abbreviations are used in the text: T3P=N-propane Phosphonic Cyclic Anhydride, EtOAc=ethyl acetate, DIPEA=N,N-diisopropylethylamine.
  • Column Phenomenex LUNA
    Detector UV
    Wavelength 220 nm
    Flow 1 mL/min
    Injection volume 1 μL
    Temperature 40° C.
    Run Time 8 min
    Mobile Phase A: 0.05% v/v TFA in water/B: 0.05% v/v TFA in
    acetonitrile
  • Gradient FAST gradient:
    Step 1: Time-Reserv.A-Reserv.B Time 0 min 100% A
    Step 2: Time-Reserv.A-Reserv.B Time 8 min 5% A
    Step 3: Time-Reserv.A-Reserv.B Time 8.01 min 100% A
  • Example 1 Preparation of 4-Methyl-5-(4-methyl-1,3-oxazol-5-yl)-2,4-dihydro-3H-1,2,4-triazole-3-thione
  • Figure US20070232808A1-20071004-C00008
  • 4-Methyl-1,3-oxazole-5-carboxylic acid (commercially available) (12.9 g, 101.5 mmol) was dissolved in DMF (60 mL) and treated with 4-methyl-3-thiosemicarbazide (11.61 g, 1.10 eq). Then DIPEA (31.0 mL, 1.75 eq) was added at 20° C. Under ice bath cooling, T3P 50% w/w in EtOAc (90 mL) was added dropwise, maintaining the temperature below 15° C. over 20 minutes. The resulting mixture was then stirred at 20° C. for 6 hours.
  • The mixture was diluted with NaOH 4 M (120.0 mL). The resulting bi-phasic mixture was allowed separating and the upper organic layer discarded. The aqueous layer (pH=8) was adjusted to pH=11 with additional NaOH 4 M (60 mL) and then heated to 70° C. (internal temperature) for 30 min. After cooling down over night, HCl 37% was slowly added until pH=5 was reached.
  • The suspension was stirred for 8 hours, then the solid was filtered and washed with water (60 mL), and it was dried in a vacuum oven at 40° C. overnight.
  • Yield: 10.48 g, 53,4 mmol, 53% th
  • 1H NMR (DMSO-d6, 600 MHz, δppm): 14.11 (bs, 1H), 8.60 (s, 1H), 3.61 (s, 3H), 2.33 (s, 3H)
  • MH+=197
  • Example 2 Preparation of 5-(2,4-dimethyl-1,3-thiazol-5-yl)-4-methyl-2,4-dihydro-3H-1,2,4-triazole-3-thione
  • Figure US20070232808A1-20071004-C00009
  • 2,4-Dimethyl-1,3-oxazole-5-carboxylic acid (commercially available) (5 g, 31.8 mmol) and 4-methyl-3-thiosemicarbazide (3.68 g, 1.10 eq) were dissolved in DMF (15 mL). Then DIPEA (10.0 mL, 1.80 eq) was added at 20° C. Under ice bath cooling, T3P 50% w/w in EtOAc (35 mL, 1.50 eq) was added dropwise, maintaining the temperature below 10° C. The resulting mixture was then stirred at 20° C. for 2 h.
  • The mixture was diluted with water (20 mL), then NaOH 4 M was added (20.0 mL). The organic phase was discarded and the aqueous phase was heated to 70° C. (internal temperature) for 90 min. After cooling down to 50° C., HCl 37% was slowly added until pH=6.5 was reached.
  • The suspension was cooled to 5° C. and the solid was filtered and washed with water, and it was then dried in a vacuum oven at 40° C. overnight.
  • Yield: 5.45 g, 24.4 mmol, 77% th
  • 1H NMR (DMSO-d6, 400 MHz, δ ppm): 14.02 (bs, 1H), 3.39 (s, 3H), 2.69 (s, 3H), 2.34 (s, 3H)
  • MH+=227
  • Example 3 Preparation of 4-methyl-5-(2-methyl-3-pyridinyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione
  • Figure US20070232808A1-20071004-C00010
  • 2-Methylnicotinic acid (commercially available) (5 g, 36.5 mmol) and 4-methyl-3-thiosemicarbazide (4.22 g, 1.10 eq) were dissolved in EtOAc (15 mL). Then DIPEA (14.5 mL, 2.28 eq) was added at 20° C. Under ice bath cooling, T3P 50% w/w in EtOAc (32.5 mL, 1.50 eq) was added drop wise, maintaining the temperature below 15° C. The resulting mixture was then stirred at 20° C. for 90 min. The mixture was diluted with water (10 mL), then NaOH 4 M was added (18.5 mL). The organic layer was discarded and the remaining aqueous layer was heated to 70° C. (internal temperature) for 2 h 45 min. After cooling down to ambient temperature, a suspension was obtained, which had a pH of about 7.5 to 8.0.
  • HCl 37% was slowly added until pH=5 was reached.
  • The solid was filtered and it was then dried in a vacuum oven at 40° C. overnight.
  • Yield: 7.04 g, 34.1 mmol, 93% th
  • 1H NMR (DMSO-d6, 600 MHz, δ ppm): 14.01 (bs, 1H), 8.66 (dd, 1H), 7.96 (dd, 1H), 7.42 (dd, 1H), 3.29 (s, 3H), 2.42 (s, 3H)
  • MH+=207
  • Example 4 Preparation of 4-methyl-5-(4-pyridazinyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione
  • Figure US20070232808A1-20071004-C00011
  • 4-Pyridazinecarboxylic acid (commercially available) (5 g, 40.3 mmol) and 4-methyl-3-thiosemicarbazide (4.66 g, 1.10 eq) were dissolved in DMF (15 mL). Then DIPEA (12.5 mL, 1.78 eq) was added at 20° C. Under ice bath cooling, T3P 50% w/w in EtOAc (36 mL, 1.50 eq) was added dropwise, maintaining the temperature below 20° C. The resulting mixture was then stirred at 20° C. for 30 min. HPLC showed a new peak at 0.6 minutes and at 2.93 min.
  • The mixture was diluted with water (20 mL), then NaOH 4 M was added (20.0 mL). The organic layer was discarted and the remaining aqueous phase was heated to 70° C. (internal temperature) for 5 h, until, by HPLC, complete conversion was observed. After cooling down to ambient temperature, a suspension was obtained, which had a pH of about 7.5 to 8.0. HCl 37% was slowly added until pH=5 was reached.
  • The solid was filtered and washed with water (3 times with 20 mL), and it was then dried in a vacuum oven at 40° C. overnight.
  • Yield: 6.37 g, 33.0 mmol, 82% th
  • 1H NMR (DMSO-d6, 500 MHz, δ ppm): 14.29 (bs, 1H), 9.58 (d, 1H), 9.47 (d, 1H), 8.09 (d, 1H), 3.64 (s, 3H)
  • MH+=194
  • Example 5 Preparation of 5-(2,4-dimethyl-1,3-oxazol-5-yl)-4-methyl-2,4-dihydro-3H-1,2,4-triazole-3-thione
  • Figure US20070232808A1-20071004-C00012
  • 4-methyl-3-thiosemicarbazide (4.5 g, 42.8 mmol) was dissolved in DMF (12.5 mL, 2.5 vol) under stirring. Commercially available 2,4-dimethyl-1,3-oxazole-5-caboxylic acid (5 g, 35.4 mmol) and DIPEA-diisopropylethylamine-(15.5 mL, 89 mmol) were added. Mixture was cooled down to 5° C. with an ice-water bath and a solution of T3P 50% w/w in ethyl acetate (45.5 mL, 76.4 mmol) was added drop wise in 15 minutes maintaining temperature below 10° C. At the end of the addition, mixture was allowed to reach ambient temperature and stirred for 2 hours under nitrogen. The mixture was diluted with 22.5 mL of water and 22.5 mL of a solution of NaOH 32% w/w under stirring (final pH=12). After separation, the upper organic layer was discarded while the water phase was heated to 70° C. (65° C. internal). The pH of the mixture was checked over time and pH adjusted to 12 if necessary. The heating was kept for a total amount of 3 hours.
  • After cooling down to ambient temperature, 2.5 mL of a solution of HCl 37% w/w were added until pH was 8. A solid started precipitating and the suspension was stirred over night.
  • The mixture was filtered, the cake washed with 22.5 mL of water and the collected solid dried under vacuum oven at 40° C. for 5 hours.
  • Yield 4.28 g; 57% theoretical
  • 1H-NMR 600 MHz, DMSO-d6: 2.26 (3H, s), 2.48 (3H, s), 3.59 (3H, s), 14.07 (1H, br. s.)
  • MH+ [211]
  • All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.
  • It is to be understood that the present invention covers all combinations of particular and preferred groups described herein above.
  • The application of which this description and claims forms part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described herein. They may take the form of product, composition, process, or use claims and may include, by way of example and without limitation, the following claims:

Claims (1)

1. Process for preparing thiazole or triazole derivatives of formula (I)
Figure US20070232808A1-20071004-C00013
in which
X may be Nitrogen or Sulfur;
Het means aryl or heteroaryl; each of which may be substituted by 1 to 4 groups J selected from:
halogen, C1-C6 alkyl C1-C6 alkoxy, halo C1-C6 alkyl C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, —C(O)R1, nitro, hydroxy, —NR2R3, cyano or a group Z;
R1 is a C1-C4 alkyl —OR3 or —NR3R4;
R2 is hydrogen or C1-C6 alkyl;
R3 is hydrogen or C1-C6 alkyl;
R is H, C1-C6 alkyl aryl, benzyl; each of which may be substituted by 1 to 4 groups J;
according to the following Scheme 1:
Figure US20070232808A1-20071004-C00014
in which
step a means a reaction in basic conditions of compounds (IIA) with 3-thiosemicarbazide derivatives, followed by a treatment with an inorganic base and n-propane phosphonic cyclic anhydride and finally pH adjustment with inorganic acids to give compounds of formula (II).
US11/693,757 2006-04-03 2007-03-30 Process for preparing heterocyclic derivatives Abandoned US20070232808A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/608,184 US7838680B2 (en) 2006-04-03 2009-10-29 Process for preparing heterocyclic derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0607899.2A GB0607899D0 (en) 2006-04-03 2006-04-03 Process for preparing heterocyclic derivatives
GB0607899.2 2006-04-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/608,184 Continuation US7838680B2 (en) 2006-04-03 2009-10-29 Process for preparing heterocyclic derivatives

Publications (1)

Publication Number Publication Date
US20070232808A1 true US20070232808A1 (en) 2007-10-04

Family

ID=36581002

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/693,757 Abandoned US20070232808A1 (en) 2006-04-03 2007-03-30 Process for preparing heterocyclic derivatives
US12/608,184 Expired - Fee Related US7838680B2 (en) 2006-04-03 2009-10-29 Process for preparing heterocyclic derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/608,184 Expired - Fee Related US7838680B2 (en) 2006-04-03 2009-10-29 Process for preparing heterocyclic derivatives

Country Status (18)

Country Link
US (2) US20070232808A1 (en)
EP (1) EP2007747B1 (en)
JP (1) JP5167242B2 (en)
KR (1) KR101411124B1 (en)
CN (1) CN101454308B (en)
AU (1) AU2007233744B2 (en)
BR (1) BRPI0710049A2 (en)
CA (1) CA2648089A1 (en)
CR (1) CR10351A (en)
EA (1) EA017304B1 (en)
ES (1) ES2443219T3 (en)
GB (1) GB0607899D0 (en)
IL (1) IL194389A0 (en)
MA (1) MA30354B1 (en)
MX (1) MX2008012876A (en)
NO (1) NO20084414L (en)
WO (1) WO2007113261A1 (en)
ZA (1) ZA200808107B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018189340A1 (en) 2017-04-14 2018-10-18 Italfarmaco S.P.A. Selective hdac6 inhibitors
WO2022029041A1 (en) 2020-08-07 2022-02-10 Italfarmaco S.P.A. 2-(4-((5-(benzo[b]thiophen-3-yl)-1h-tetrazol-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (hdac6) for use in treating e.g. peripheral neuropathy

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3995C2 (en) * 2009-05-11 2010-07-31 Государственный Университет Молд0 Use of di(m-Ophenoxy)-di{[2-(4-aminobenzenesulfamido)-5-ethyl-1,3,4-thiadiazole]-3,5-dibromosalicylidenethiosemicarbazonato(-1)-copper} as inhibitor of mammary cancer T-47D cell proliferation
CN106866657A (en) * 2017-04-25 2017-06-20 成都倍特药业有限公司 A kind of preparation method of ergometrine
US9862675B1 (en) 2017-07-05 2018-01-09 King Fahd University Of Petroleum And Minerals Method of N-formylating amines with a phosphonic anhydride

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032238A1 (en) * 2000-07-08 2002-03-14 Henning Priepke Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10033337A1 (en) * 2000-07-08 2002-01-17 Boehringer Ingelheim Pharma Biphenylcarboxamides, their preparation and their use as medicaments
AU1697502A (en) * 2000-10-20 2002-04-29 Rhodia Acetow Gmbh Highly compressed filter tow bales
PT2060570E (en) 2004-02-23 2012-05-07 Glaxo Group Ltd Azabicyclo[3.1.0] hexane derivatives useful as modulators of dopamine d3 receptors
GB0517193D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032238A1 (en) * 2000-07-08 2002-03-14 Henning Priepke Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018189340A1 (en) 2017-04-14 2018-10-18 Italfarmaco S.P.A. Selective hdac6 inhibitors
US11351178B2 (en) 2017-04-14 2022-06-07 Italfarmaco Spa Selective HDAC6 inhibitors
WO2022029041A1 (en) 2020-08-07 2022-02-10 Italfarmaco S.P.A. 2-(4-((5-(benzo[b]thiophen-3-yl)-1h-tetrazol-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (hdac6) for use in treating e.g. peripheral neuropathy

Also Published As

Publication number Publication date
BRPI0710049A2 (en) 2011-08-02
EA200870405A1 (en) 2009-04-28
MA30354B1 (en) 2009-04-01
EP2007747A1 (en) 2008-12-31
EA017304B1 (en) 2012-11-30
US7838680B2 (en) 2010-11-23
US20100048895A1 (en) 2010-02-25
GB0607899D0 (en) 2006-05-31
JP2009532428A (en) 2009-09-10
KR101411124B1 (en) 2014-06-25
ES2443219T3 (en) 2014-02-18
MX2008012876A (en) 2008-10-13
CN101454308B (en) 2013-05-08
CA2648089A1 (en) 2007-10-11
JP5167242B2 (en) 2013-03-21
KR20080108328A (en) 2008-12-12
ZA200808107B (en) 2009-10-28
WO2007113261A1 (en) 2007-10-11
AU2007233744A1 (en) 2007-10-11
IL194389A0 (en) 2009-08-03
NO20084414L (en) 2008-10-28
AU2007233744B2 (en) 2012-09-06
EP2007747B1 (en) 2013-11-20
CN101454308A (en) 2009-06-10
CR10351A (en) 2008-10-29

Similar Documents

Publication Publication Date Title
EP2602260B1 (en) Process for preparing compound having hiv integrase inhibitory activity
RU2476430C2 (en) Aminodihydrothiazine derivatives substituted by cyclic group
JP6618120B2 (en) Heterocyclic and carbocyclic derivatives having TrkA inhibitory activity
JP7305196B2 (en) SSAO/VAP-1 inhibitors of haloallylamines and uses thereof
WO2007082131A1 (en) Process for the preparation of hydroxy substituted heterocycles
CN110997644A (en) Preparation of substituted 3-aryl-5-trifluoromethyl-1, 2, 4-oxadiazoles
US7838680B2 (en) Process for preparing heterocyclic derivatives
AU2013255437A1 (en) Substituted pyridine compounds as CRAC modulators
WO2015147247A1 (en) Tricyclic derivative having hiv replication inhibitory activity
EP2513111A1 (en) Mk2 inhibitors
WO2016098793A1 (en) Thiazole derivative having cyclic guanidyl group
WO2013024427A1 (en) Novel urea derivatives as tec kinase inhibitors and uses thereof
CN117751113A (en) Aromatic acetylene derivative and preparation method and application thereof
WO2013050341A1 (en) Azabenzoxazine derivatives as crac modulators
JP2014080395A (en) Aminolactam derivatives and pharmaceutical compositions containing the same
TWI813725B (en) A novel process for the preparation of anthranilic diamides
WO2013050270A1 (en) Benzoxazine derivatives as crac modulators
KR20080002937A (en) Process for preparing bicyclic compounds
US20220227723A1 (en) 2,3-diaryl-1,3-thiazepan-4-ones compounds and methods for making
US20230357155A1 (en) Improved synthesis of 4-amino-6-(heterocyclic)picolinates
CA3219259A1 (en) A novel process for the preparation of anthranilic diamides
Katkevics et al. Interaction of Hydroxylamine with Esters of 2-Oxobutenoic Acids. Synthesis of 1-Hydroxy-3-hydroximino-2-pyrrolidinones
BR112019015231A2 (en) processes for the preparation of compounds and compounds
Hernández et al. On the reaction of 3-nitroimidazo [1, 2-a] pyridine-2-carbonitrile with amino acid derivatives
JP2014080394A (en) Imidazoimidazolone derivatives and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
AS Assignment

Owner name: GLAXO GROUP LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BACCHI, SERGIO;REEL/FRAME:019261/0642

Effective date: 20070503

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE

AS Assignment

Owner name: GLAXO GROUP LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BACCHI, SERGIO;REEL/FRAME:024778/0806

Effective date: 20070503